연구용
Chloroquine diphosphate ATM/ATR 활성제
제품 번호S4157
화학 구조
분자량: 515.86
바로가기
품질 관리
배치:
순도:
99.97%
99.97
세포 배양, 처리 및 작업 농도
| 세포주 | 분석 유형 | 농도 | 배양 시간 | 제형 | 활성 설명 | PMID |
|---|---|---|---|---|---|---|
| human K562 cells | Cytotoxic assay | Cytotoxicity against human K562 cells by MTT assay, IC50=31.83 nM | 18538567 | |||
| human KB cells | Cytotoxic assay | Cytotoxicity against human KB cells by microplate method, IC50=0.6 μM | 14640524 | |||
| human MDA-MB-468 cells | Cytotoxic assay | 48 h | Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=2.81 μM | 19945197 | ||
| human MCF7 cells | Cytotoxic assay | 48 h | Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one, GI50=5.51 μM | 19945197 | ||
| human MDA-MB-231 cells | Cytotoxic assay | 48 h | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride, GI50=6.08 μM | 19945197 | ||
| human HeLa cells | Cytotoxic assay | Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay, IC50=30 μM | 24354322 | |||
| human HepG2 cells | Cytotoxic assay | 48 h | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay, IC50=37.68 μM | 23815186 | ||
| mammary tumor FM3A | Cytotoxicity assay | Cytotoxicity of compound was tested against mouse mammary tumor FM3A cells, EC50 = 0.0000003 μM. | 12570385 | |||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against Plasmodium falciparum FcB1/Columbia infected in human red blood cells assessed as parasite growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.00011 μM. | 25659770 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine and pyrimethamine-resistant ring stage Plasmodium falciparum V1/S infected in human red blood cells after 48 hrs, IC50 = 0.0055 μM. | 21207937 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium ovale ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.0078 μM. | 20937779 | |||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-sensitive erythrocytic stage of Plasmodium falciparum NF54 infected in human red blood cells assessed as growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.0094 μM. | 23685569 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.01 μM. | 21155593 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.011 μM. | 28222317 | |||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.012 μM. | 25311562 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium malariae ring stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.014 μM. | 20937779 | |||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-sensitive, mefloquine-resistant ring stage Plasmodium falciparum D6 infected in human red blood cells after 48 hrs, IC50 = 0.0142 μM. | 21207937 | ||
| red blood cells | Antiplasmodial assay | 72 hrs | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human red blood cells after 72 hrs by parasite lactate dehydrogenase assay, IC50 = 0.0143 μM. | 22917857 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum NF54 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50 = 0.016 μM. | 30296683 | ||
| red blood cells | Antimalarial assay | 96 hrs | Antimalarial activity against wild type early trophozoite stage of Plasmodium falciparum D6 in human red blood cells assessed as [3H]hypoxanthine uptake after 96 hrs, IC50 = 0.017 μM. | 23448281 | ||
| FM3A | Function assay | Selectivity for FM3A cells over Plasmodium falciparum as mean EC50 ratio, IC50 = 0.019 μM. | 12408708 | |||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.02 μM. | 21155593 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.02 μM. | 25311562 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected with human red blood cells incubated for 48 hrs by SYBR Green method, IC50 = 0.023 μM. | 25725608 | |||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium ovale trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.0232 μM. | 20937779 | |||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium falciparum 3D7 A infected in red blood cells assessed as inhibition of [3H]hypoxanthine incorporation after 24 hrs by scintillation counting, IC50 = 0.024 μM. | 24900261 | |||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum Nigerian infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.025 μM. | 28800458 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis, IC50 = 0.026 μM. | 30199706 | ||
| HCT-8 | Antimicrobial assay | 48 hrs | Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA, IC50 = 0.027 μM. | 18591280 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human type A-positive red blood cells assessed as parasite lactate dehydrogenase activity after 72 hrs by spectrophotometric analysis, IC50 = 0.029 μM. | 22054038 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay, IC50 = 0.03 μM. | 21123074 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in red blood cells after 72 hrs by SYBR green 1 staining based fluorometric assay, IC50 = 0.03 μM. | 27692831 | |||
| 3D7 | Antiplasmodial assay | Antiplasmodial activity against Plasmodium falciparum 3D7 ring stage cells assessed as reduction parasitemia by Malstat assay, IC50 = 0.03 μM. | 22858300 | |||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium falciparum 3D7A infected in red blood cells assessed as inhibition of parasite growth after 24 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.036 μM. | 25906200 | |||
| red blood cells | Antimalarial assay | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in human red blood cells assessed as reduction in parasitic LDH activity by Malstat reagent based spectrophotometric method, IC50 = 0.04 μM. | 28800458 | |||
| red blood cells | Antiplasmodial assay | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.04 μM. | 28315598 | |||
| red blood cells | Antiplasmodial assay | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in red blood cells after 72 hrs by parasitic LDH assay, IC50 = 0.04 μM. | 24900509 | |||
| Vero | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs, IC50 = 0.05 μM. | 19833520 | ||
| red blood cells | Antiplasmodial assay | 4 hrs | Antiplasmodial activity against Plasmodium falciparum in human red blood cells after 4 hrs, IC50 = 0.055 μM. | 17990865 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-sensitive ring stage Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs, IC50 = 0.089 μM. | 21207937 | ||
| B-cells | Function assay | Concentration required for half-maximal inhibition of CpG-ODN effect on thymidine uptake by WEHI 231 murine B-cells in the presence of alpha-sIgM., EC50 = 0.11 μM. | 10406648 | |||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine and pyrimethamine resistant Plasmodium falciparum K1 infected in human red blood cells assessed as reduction in parasite viability after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.12 μM. | 25746816 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]-hypoxanthine incorporation incubated for 48 hrs prior to [3H]-hypoxanthine addition measured after 24 hrs by li, IC50 = 0.125 μM. | 24268543 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against Plasmodium malariae trophozoite stage infected in red blood cells in presence of AB+ human serum by drug susceptibility assay, IC50 = 0.1279 μM. | 20937779 | |||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcB1 infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.132 μM. | 28800458 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-resistant ring stage Plasmodium falciparum W2 infected in human red blood cells after 48 hrs, IC50 = 0.138 μM. | 21207937 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells assessed as inhibition of ring-stage parasite growth after 48 hrs by flow cytometry, IC50 = 0.14 μM. | 21295887 | ||
| RPMI1640 | Antiparasitic assay | 72 hrs | Antiparasitic activity against chloroquine-resistant erythrocytic stage of Plasmodium falciparum K1 infected in human RPMI1640 cells after 72 hrs by NBT staining based spectroscopic analysis, IC50 = 0.14 μM. | 26922226 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine/pyrimethamine resistant Plasmodium falciparum K1 infected in human red blood cells after 48 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.15 μM. | 27344215 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against asexual erythrocyte stage of chloroquine-resistant Plasmodium falciparum Dd2 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50 = 0.15 μM. | 30296683 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as 3H-hypoxanthine incorporation after 48 hrs by liquid scintillation counting, IC50 = 0.17 μM. | 21644541 | ||
| L6 | Antiparasitic assay | 48 hrs | Antiparasitic activity against Plasmodium falciparum K1 infected in rat L6 cells assessed as inhibition of parasite growth preincubated for 48 hrs before [3H]hypoxanthine addition measured after 24 hrs by [3H]hypoxanthine incorporation assay, IC50 = 0.178 μM. | 21937228 | ||
| L6 | Cytotoxicity assay | Cytotoxicity against rat L6 cells by alamar blue assay, IC50 = 0.1885 μM. | 17178177 | |||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against the multidrug-resistant Plasmodium falciparum FRC-3 infected in human red blood cells assessed as reduction in parasite growth after 48 hrs by Hoechst 33342 staining based flow cytometric analysis, IC50 = 0.207 μM. | 30199706 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-resistant erythrocytic stage of Plasmodium falciparum K1 infected in human red blood cells assessed as growth inhibition after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.21 μM. | 23685569 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine- and pyrimethamine-resistant Plasmodium falciparum K1 infected in human red blood cells assessed as [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting, IC50 = 0.22 μM. | 21438586 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against ring stage Plasmodium falciparum W2 infected with human red blood cells incubated for 48 hrs by flow cytometry, IC50 = 0.229 μM. | 25725608 | |||
| L6 | Antiparasitic assay | Antiparasitic activity against chloroquine, pyrimethamine-resistant Plasmodium falciparum K1 erythrocyte stage infected rat L6 cells, IC50 = 0.23 μM. | 17949068 | |||
| L6 | Antiplasmodial assay | Antiplasmodial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in rat L6 cells, IC50 = 0.25 μM. | 19942439 | |||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human A-positive red blood cells after 72 hrs by lactate dehydrogenase assay, IC50 = 0.25 μM. | 21123074 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum FcM29 infected in human red blood cells after 48 hrs by [3H]-hypoxanthine incorporation assay, IC50 = 0.26 μM. | 28800458 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90-C2B infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.28 μM. | 21155593 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against ring stage Plasmodium falciparum Dd2 infected with human red blood cells incubated for 48 hrs by SYBR Green method, IC50 = 0.285 μM. | 25725608 | ||
| red blood cells | Antimalarial assay | 96 hrs | Antimalarial activity against chloroquine and pyrimethamine-resistant early trophozoite stage of Plasmodium falciparum W2 in human red blood cells assessed as [3H]hypoxanthine uptake after 96 hrs, IC50 = 0.29 μM. | 23448281 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as growth inhibition after 72 hrs by spectrophotometrically, IC50 = 0.316 μM. | 25311562 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.317 μM. | 28222317 | ||
| red blood cells | Antiplasmodial assay | 72 hrs | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 72 hrs by parasite lactate dehydrogenase assay, IC50 = 0.3171 μM. | 22917857 | ||
| red blood cells | Antiplasmodial assay | 72 hrs | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by parasitic LDH assay, IC50 = 0.39 μM. | 24900509 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.4 μM. | 21155593 | ||
| red blood cells | Antimalarial assay | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells assessed as reduction in parasitic LDH activity by Malstat reagent based spectrophotometric method, IC50 = 0.42 μM. | 28800458 | |||
| red blood cells | Antiplasmodial assay | 72 hrs | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by Malstat reagent based LDH assay, IC50 = 0.43 μM. | 28315598 | ||
| Vero | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs, IC50 = 0.484 μM. | 19833520 | ||
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay, IC50 = 0.49 μM. | 29236492 | ||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human type A-positive red blood cells assessed as parasite lactate dehydrogenase activity after 72 hrs by spectrophotometric analysis, IC50 = 0.52 μM. | 22054038 | ||
| red blood cells | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human red blood cells after 48 hrs by SYBR test, IC50 = 0.59 μM. | 26988303 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against multidrug-resistant Plasmodium falciparum TM93-C1088 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.62 μM. | 21155593 | ||
| Dd2 | Antiplasmodial assay | Antiplasmodial activity against drug resistant Plasmodium falciparum Dd2 ring stage cells assessed as reduction parasitemia by Malstat assay, IC50 = 0.71 μM. | 22858300 | |||
| red blood cells | Antimalarial assay | 72 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in red blood cells after 72 hrs by SYBR green 1 staining based fluorometric assay, IC50 = 0.75 μM. | 27692831 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine, pyrimethamine, and mefloquine-resistant Plasmodium falciparum Dd2 infected in human O positive red blood cells assessed as inhibition of [3H]-hypoxanthine uptake after 48 hrs, IC50 = 0.98 μM. | 21155593 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay, CC50 = 1.6 μM. | 25791675 | ||
| HepG2 | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis, IC50 = 1.65 μM. | 25791675 | ||
| WI38 | Antiviral assay | 2 hrs | Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay, EC50 = 1.7 μM. | 17893158 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 100 uM ZnCl2, GI50 = 2.1 μM. | 19748786 | ||
| SMB | Antiprion assay | Antiprion activity against Chandler strain of sheep scrapie prion protein infected in mouse SMB cells assessed as clearance of disease-associated scrapie prion protein, EC50 = 2.3 μM. | 21570837 | |||
| HEK293 | Function assay | Inhibition of human ERG expressed in HEK293 cells assessed as reduction in tail current at membrane potential of +20 mV, IC50 = 2.5 μM. | 25746816 | |||
| red blood cells | Antimalarial assay | 24 hrs | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in red blood cells assessed as reduction in mature schizonts formation after 24 hrs by Giemsa-staining based assay, EC50 = 2.97 μM. | 29499486 | ||
| HEK293 | Function assay | hERG binding assays: Displacement of [3H]-Dofetilide (5 nM final) from hERG membranes obtained from HEK293 cells, Ki = 3.16228 μM. | 32353859 | |||
| 1205 Lu | Cytotoxicity assay | 72 hrs | Cytotoxicity against human 1205 Lu cells after 72 hrs by MTT assay, IC50 = 3.6 μM. | 25699157 | ||
| LN229 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LN229 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. | 25699157 | ||
| C8161 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human C8161 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. | 25699157 | ||
| HT-29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 3.6 μM. | 25699157 | ||
| WI38 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human WI38 cells assessed as inhibition of proliferation after 24 hrs by SRB assay, IC50 = 3.63 μM. | 25461309 | ||
| ScN2a | Function assay | Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells, EC50 = 4 μM. | 12904059 | |||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells after 24 hrs by neutral red dye uptake assay, TC50 = 4.3 μM. | 22783984 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 50 uM CuCl2, GI50 = 4.4 μM. | 19748786 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 10 uM CuCl2, GI50 = 5.3 μM. | 19748786 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 50 uM ZnCl2, GI50 = 5.6 μM. | 19748786 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 1 uM CuCl2, GI50 = 6.1 μM. | 19748786 | ||
| SH-SY5Y | Function assay | 24 hrs | Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 40 residues) production measured after 24 hrs, IC50 = 7 μM. | 29559198 | ||
| SH-SY5Y | Function assay | 24 hrs | Inhibition of BACE1 in human SH-SY5Y cells harboring wild type APP695 assessed as reduction in amyloid beta (1 to 40) level after 24 hrs by ELISA method, IC50 = 7 μM. | 30268822 | ||
| CHO | Function assay | Inhibition of human ERG expressed in CHO cells, Ki = 7.5 μM. | 24900603 | |||
| L6 | Cytotoxicity assay | Cytotoxicity against L6 cells, IC50 = 7.7 μM. | 17280835 | |||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by alamar blue assay, IC50 = 8.3 μM. | 21155593 | ||
| WI38 | Cytotoxicity assay | 2 hrs | Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay, CC50 = 8.5 μM. | 17893158 | ||
| HepG2 | Antimalarial assay | Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells, IC50 = 9 μM. | 26640981 | |||
| SKHep | Growth inhibition assay | 48 hrs | Growth inhibition of human SKHep cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 9.5 μM. | 19748786 | ||
| HeLa | Cytotoxicity assay | 7 hrs | Cytotoxicity against human HeLa cells assessed as cell survival after 7 hrs by MTT assay, IC50 = 9.665 μM. | 17768052 | ||
| HeLa | Cytotoxicity assay | 7 days | Cytotoxicity against human HeLa cells after 7 days by MTT assay, IC50 = 9.67 μM. | 21489789 | ||
| K562 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human K562 cells assessed as radioactive thymidine incorporation after 24 hrs, CC50 = 9.7 μM. | 18680278 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days, EC50 = 10 μM. | 25970561 | ||
| PDAC | Function assay | Inhibition of cell proliferation of PDAC cells (unknown origin), IC50 = 10 μM. | 26135471 | |||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Chikungunya virus 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 10 μM. | 24926807 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by CellTiter-Glo assay, EC50 = 10.1 μM. | 29800827 | ||
| BT-483 | Growth inhibition assay | 48 hrs | Growth inhibition of human BT-483 cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 10.2 μM. | 19748786 | ||
| Vero | Antiviral assay | 5 days | Antiviral activity against Chikungunya virus Indian Ocean 889 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTS/PMS method, EC50 = 11 μM. | 29336951 | ||
| Vero A | Antiviral assay | 6 to 7 days | Antiviral activity against Chikungunya virus Indian ocean strain 899 infected in African green monkey Vero A cells assessed as reduction in viral-induced cytopathic effect after 6 to 7 days by MTS/PMS assay, EC50 = 11 μM. | 28671832 | ||
| Vero | Antiviral assay | 5 days | Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured on day 5 post infection by MTS/PMS assay, EC50 = 11 μM. | 29499487 | ||
| Vero | Antiviral assay | 7 days | Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 7 days by MTS/PMS method, EC50 = 11 μM. | 24800626 | ||
| Vero | Antiviral assay | 7 days | Antiviral activity against Sindbis virus strain HRsp infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 11 μM. | 25946116 | ||
| Vero | Antiviral assay | 7 days | Antiviral activity against Chikungunya virus strain 899 infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 11 μM. | 25946116 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Sindbis virus HRsp infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 11 μM. | 24926807 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Sindbis virus HRsp infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 11 μM. | 23215460 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Chikungunya virus 899 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 11 μM. | 23215460 | ||
| red blood cells | Antimalarial assay | 48 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum K14 infected in human red blood cells after 48 hrs by [3H]hypoxanthine incorporation assay, IC50 = 11 μM. | 25282260 | ||
| red blood cells | Antimalarial assay | 24 hrs | Antimalarial activity against chloroquine-resistant Plasmodium falciparum RKL9 infected in red blood cells assessed as reduction in mature schizonts formation after 24 hrs by Giemsa-staining based assay, EC50 = 11.25 μM. | 29499486 | ||
| MCF7 | Cytotoxicity assay | Cytotoxicity against human MCF7 cells assessed as [3H]hypoxanthine incorporation, IC50 = 12 μM. | 18512987 | |||
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HEK293 cells after 72 hrs by alamar blue assay, IC50 = 12 μM. | 21155593 | ||
| Vero | Antiviral assay | 24 hrs | Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication after 24 hrs by RT-PCR method, EC50 = 12 μM. | 28068604 | ||
| Vero | Antiviral assay | 24 hrs | Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral RNA replication after 24 hrs by RT-PCR method, EC50 = 12 μM. | 28092859 | ||
| HeLa | Antiviral assay | 48 hrs | Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry, IC50 = 12.48 μM. | 22858300 | ||
| SH-SY5Y | Function assay | 24 hrs | Inhibition of BACE1 in human SH-SY5Y cells harboring wild type APP695 assessed as reduction in amyloid beta (1 to 42) level after 24 hrs by ELISA method, IC50 = 12.7 μM. | 30268822 | ||
| SH-SY5Y | Function assay | 24 hrs | Modulation of human wild-type APP695 expressed in SH-SY5Y cells assessed as inhibition of amyloid beta (1 to 42 residues) production measured after 24 hrs by ELISA, IC50 = 12.8 μM. | 29559198 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by Alamar Blue assay, IC50 = 12.9 μM. | 21190857 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Semliki forest virus Vietnam infected in African green monkey Vero cells assessed as inhibition of virus-induced cell death after 6 to 7 days by MTS assay, EC50 = 13.8 μM. | 24926807 | ||
| Vero | Antiviral assay | 7 days | Antiviral activity against Semliki forest virus strain Vietnam infected in african green monkey Vero cells assessed as inhibition of virus induced cell death measured after 7 days, EC50 = 14 μM. | 25946116 | ||
| Vero | Antiviral assay | 6 to 7 days | Antiviral activity against Semliki forest virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect incubated for 6 to 7 days by MTS assay, EC50 = 14 μM. | 23215460 | ||
| NSO | Cytotoxicity assay | Cytotoxicity against mouse NSO cells by MTT assay, TC50 = 14.9 μM. | 19113955 | |||
| L1210 | Cytotoxicity assay | Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 15 μM. | 26114811 | |||
| Huh-7 | Antiplasmodial assay | 48 hrs | Antiplasmodial activity against Plasmodium berghei liver stage form transfected in human Huh-7 cells assessed as cell viability after 48 hrs by luciferase reporter gene assay, IC50 = 15.9 μM. | 23273038 | ||
| Daudi | Cytotoxicity assay | Cytotoxicity against human Daudi cells by MTT assay, TC50 = 16.7 μM. | 19113955 | |||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 18 μM. | 26114811 | |||
| J774.1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against mouse J774.1 cells after 24 hrs by AlamarBlue based cytotoxicity assay, IC50 = 18.4 μM. | 27316542 | ||
| HeLa | Growth inhibition assay | 48 hrs | Growth inhibition of human HeLa cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 18.6 μM. | 19748786 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, CC50 = 19.4 μM. | 20014857 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by XTT reduction assay, CC50 = 19.4 μM. | 24686013 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 48 hrs by XTT assay, CC50 = 19.4 μM. | 24594524 | ||
| MDA-MB-468 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-468 cells after 72 hrs by SRB assay, IC50 = 19.86 μM. | 26602827 | ||
| KB | Cytotoxicity assay | 48 hrs | Cytotoxicity against human KB cells after 48 hrs by MTT assay, IC50 = 20.4 μM. | 11809075 | ||
| Vero | Antiviral assay | 5 days | Antiviral activity against Chikungunya virus Indian Ocean 889 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTS/PMS method, EC90 = 21 μM. | 29336951 | ||
| Vero | Antiviral assay | Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured on day 5 post infection by MTS/PMS assay, EC90 = 21 μM. | 29499487 | |||
| Vero | Antiviral assay | 7 days | Antiviral activity against Chikungunya virus Indian Ocean strain 899 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 7 days by MTS/PMS method, EC90 = 21 μM. | 24800626 | ||
| Vero | Cytotoxicity assay | 72 hrs | Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay, IC50 = 21 μM. | 23727538 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells after 48 hrs by lactate dehydrogenase assay, GI50 = 22.16 μM. | 21882831 | ||
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by MTS assay, IC50 = 22.5 μM. | 19879150 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 22.52 μM. | 19804979 | ||
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human p53, pRB mutant and estrogen receptor deficient MDA-MB-231 cells after 48 hrs by SRB assay, GI50 = 22.52 μM. | 20561720 | ||
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 22.52 μM. | 28586716 | ||
| CEM | Cytotoxicity assay | Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation by Coulter counter analysis, IC50 = 23 μM. | 26114811 | |||
| CE81T | Growth inhibition assay | 48 hrs | Growth inhibition of human CE81T cells after 48 hrs by MTT assay in presence of 10% FBS supplemented DMEM medium, GI50 = 23.4 μM. | 19748786 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 23.43 μM. | 26135471 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells assessed as intracellular ATP level after 72 hrs by Celltiter-Glo luminescent assay, EC50 = 25 μM. | 21910466 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 25 μM. | 26135471 | ||
| BxPC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human BxPC3 cells after 72 hrs by SRB method, IC50 = 25 μM. | 25699157 | ||
| MDA-MB-468 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay, GI50 = 28.58 μM. | 19804979 | ||
| MDA-MB-468 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay, GI50 = 28.58 μM. | 20106668 | ||
| MDA-MB-468 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 28.58 μM. | 28586716 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against human K562 cells by MTT assay, IC50 = 29.03 μM. | 18562202 | |||
| HeLa | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay, IC50 = 29.96 μM. | 26602827 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 30 μM. | 19482476 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 30 μM. | 19926173 | ||
| HepG2 | Cytotoxicity assay | Cytotoxicity against human HepG2 cells by MTT assay, IC50 = 30 μM. | 17981462 | |||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 21741131 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 22889559 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 24946216 | ||
| SH-SY5Y | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay, CC50 = 30 μM. | 29559198 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 24858543 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells measured after 72 hrs by MTT assay, CC50 = 30 μM. | 27155463 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay, CC50 = 30 μM. | 25791675 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay, CC50 = 30 μM. | 25282267 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 21852132 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, CC50 = 30 μM. | 22608675 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay, CC50 = 30 μM. | 27654395 | ||
| KB | Cytotoxicity assay | Cytotoxicity against human KB cells by SRB assay, ED50 = 30.8 μM. | 16562832 | |||
| HepG2 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by neutral red uptake assay, TC50 = 31 μM. | 23145816 | ||
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50 = 32 μM. | 19482476 | ||
| K562 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human K562 cells after 72 hrs by flow cytometry, IC50 = 32 μM. | 19926173 | ||
| FM3A | Antiproliferative assay | Antiproliferative activity against Mouse mammary tumor FM3A cells, EC50 = 32 μM. | 10966746 | |||
| FM3A | Cytotoxicity assay | In vitro cytotoxicity against mouse mammary FM3A cells, EC50 = 32 μM. | 12036365 | |||
| FM3A | Cytotoxicity assay | Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host, EC50 = 32 μM. | 11855978 | |||
| FM3A | Cytotoxicity assay | Cytotoxicity against FM3A mouse mammary cells, EC50 = 32 μM. | 13678413 | |||
| FM3A | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse FM3A cells assessed as inhibition of increase in cell density after 48 hrs, EC50 = 32 μM. | 18479926 | ||
| FM3A | Cytotoxicity assay | Compound was tested for cytotoxicity against FM3A mouse mammary cells. , EC50 = 32 μM. | 10447961 | |||
| LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells assessed as reduction in cell number incubated for 72 hrs, IC50 = 32.87 μM. | 26135471 | ||
| HCT116 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HCT116 cells after 72 hrs by WST1 assay, IC50 = 33.7 μM. | 12398531 | ||
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by SRB assay, ED50 = 33.7 μM. | 9917283 | ||
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by Alamar blue assay, IC50 = 34 μM. | 24900724 | ||
| CHO | Cytotoxicity assay | Cytotoxicity against CHO cells by MTT assay, IC50 = 35.8 μM. | 26832222 | |||
| KB | Cytotoxicity assay | Cytotoxicity against human KB cells assessed as growth inhibition, IC50 = 35.95 μM. | 21705220 | |||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50 = 36.1 μM. | 19892554 | ||
| MDA-MB-231 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay, IC50 = 36.53 μM. | 26602827 | ||
| NFF | Cytotoxicity assay | 3 days | Cytotoxicity against human NFF cells after 3 days by sulforhodamine B assay, IC50 = 37.3 μM. | 23117170 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. | 19804979 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. | 20106668 | ||
| p53+/- MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human p53+/- MCF7 cells after 48 hrs by SRB assay, GI50 = 38.44 μM. | 20561720 | ||
| MCF7 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay, IC50 = 38.44 μM. | 28586716 | ||
| Caco2 | Antiproliferative assay | 2 days | Antiproliferative activity against human Caco2 cells after 2 days by sulforhodamine B assay, GI50 = 38.67 μM. | 24184076 | ||
| THP1 | Cytotoxicity assay | Cytotoxicity against human THP1 cells by MTT assay, IC50 = 40 μM. | 17981462 | |||
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human THP1 cells after 72 hrs by propidium iodide staining-based flow cytometry, IC50 = 40 μM. | 19748781 | ||
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay, IC50 = 40 μM. | 19914747 | ||
| THP1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human THP1 cells using propidium iodide staining after 72 hrs by flow cytometry, IC50 = 40 μM. | 20638854 | ||
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay, IC50 = 40 μM. | 28774427 | ||
| NCH-89 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human carmustine-resistant NCH-89 cells assessed as BrdU incorporation after 48 hrs, IC50 = 41.2 μM. | 20329733 | ||
| HepG2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth after 48 hrs by LDH assay, GI50 = 43.09 μM. | 25684422 | ||
| L6 | Toxicity assay | Toxicity against rat L6 cells, IC50 = 43.1 μM. | 19781948 | |||
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by alamar blue assay, CC50 = 44 μM. | 20014857 | ||
| MKN28 | Antiproliferative assay | 2 days | Antiproliferative activity against human MKN28 cells after 2 days by sulforhodamine B assay, GI50 = 44.44 μM. | 24184076 | ||
| NFF | Cytotoxicity assay | Cytotoxicity against human NFF cells, IC50 = 46.608 μM. | 30245402 | |||
| J774 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay, EC50 = 47.2 μM. | 29215279 | ||
| HEK293 | Cytotoxicity assay | 72 hrs | Cytotoxicity against HEK293 cells after 72 hrs by Alamar Blue assay, IC50 = 48 μM. | 21190857 | ||
| MRC5 | Cytotoxicity assay | Cytotoxicity against MRC5 cells | 17166718 | |||
| HeLa | Function assay | 10 uM | 1 hr | Stimulation of reactive oxygen species in human HeLa cells at 10 uM in presence of 10 uM CuCl2 after 1 hr by dihydroethidium dye based fluorescence assay | 19748786 | |
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | |||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| HEK293 | Autophagy assay | 10 uM | 8 hrs | Induction of autophagy in HEK293 cells assessed as increase in p62 level at 10 uM after 8 hrs by immunoblot analysis | 28481536 | |
| HEK293 | Autophagy assay | 10 uM | 8 hrs | Induction of autophagy in HEK293 cells assessed as increase in LC3-2 level at 10 uM after 8 hrs by immunoblot analysis | 28481536 | |
| LNCAP | Function assay | Reduction in GFP expression in human LNCAP cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose | 26135471 | |||
| SKBR3 | Function assay | Reduction in GFP expression in human SKBR3 cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose | 26135471 | |||
| HepG2 | Function assay | Reduction in GFP expression in human HepG2 cells transfected with plasmids co-expressing GFP and shRNAs against REV-ERBbeta followed by compound treatment 24 hrs post-transfection and measured 48 hrs post dose | 26135471 | |||
| H460 | Apoptosis assay | 25 to 75 uM | 24 hrs | Induction of apoptosis in human H460 cells at 25 to 75 uM after 24 hrs by annexin-V staining-based flow cytometry | 25699157 | |
| HepG2 | Function assay | 50 uM | 6 hrs | Reduction in lysosomal acidification in human HepG2 cells at 50 uM after 6 hrs by DAPI/lyso tracker red-double staining based confocal microscopic analysis relative to control | 28197320 | |
| 클릭하여 더 많은 세포주 실험 데이터 보기 | ||||||
화학 정보, 보관 및 안정성
| 분자량 | 515.86 | 화학식 | C18H26ClN3.2H3O4P |
보관 (수령일로부터) | |
|---|---|---|---|---|---|
| CAS 번호 | 50-63-5 | SDF 다운로드 | 원액 보관 |
|
|
| 동의어 | N/A | Smiles | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O | ||
용해도
|
In vitro |
Water : 100 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
몰농도 계산기
희석 계산기
분자량 계산기
|
In vivo |
|||||
생체 내 제형 계산기 (투명한 용액)
1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)
mg/kg
g
μL
2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
계산 결과:
작업 농도: mg/ml;
DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.
생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.
참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.
작용 메커니즘
| Targets/IC50/Ki |
TLR3
TLR7
TLR8
TLR9
ATM
(Cell-free assay) |
|---|---|
| 시험관 내(In vitro) |
Chloroquine은 말라리아의 임상 치료를 위한 화학 요법제입니다. Chloroquine은 DNA에 결합하여 DNA 복제 및 RNA 합성을 억제하여 세포 사멸을 유도합니다. Chloroquine의 효과는 독성 헤모-Chloroquine 복합체 형성N과도 관련이 있을 수 있습니다. Chloroquine은 액포 pH를 증가시키고 액포성 인지질분해효소, 액포성 프로테아제 및 헴 폴리메라아제의 활성을 억제하여 트로포조이트 헤모글로빈 분해를 억제합니다. Chloroquine은 명확한 항류마티스 특성을 가지고 있습니다. Chloroquine은 종양 괴사 인자와 인터루킨 6의 생산/방출을 억제하는 면역 조절 효과를 가집니다. 또한, Chloroquine은 플라비바이러스, 레트로바이러스, 코로나바이러스를 포함한 여러 바이러스의 복제에서 pH 의존적 단계를 억제하여 직접적인 항바이러스 효과를 발휘합니다. 가장 잘 연구된 효과는 HIV 복제에 대한 것입니다. Chloroquine은 이온 트랩을 통해 대식세포 파골리소좀 내부에 축적될 수 있으며, 여기서 Histoplasma capsulatum 및 Cryptococcus neoformans에 대해 상이한 메커니즘을 통해 강력한 항진균 활성을 발휘합니다. Chloroquine은 pH 의존적 철 결핍을 통해 H. capsulatum의 성장을 억제하는 반면, C. neoformans에는 직접적으로 독성입니다. |
| 생체 내(In vivo) |
Chloroquine은 삼중 음성 유방암에서 종양 억제 및 종양 촉진 효과를 모두 가집니다. |
참조 |
|
적용 분야
| 방법 | 바이오마커 | 이미지 | PMID |
|---|---|---|---|
| Western blot | p62 / LC3 ZEBRA / p-S824 KAP1 |
|
26677873 |
| Immunofluorescence | SQSTM1 / MAP1LC3B CD1d-β2m / LAMP1 p-S824 KAP1 / ZEBRA |
|
29872540 |
| Growth inhibition assay | Cell viability |
|
25521075 |
임상시험 정보
(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)
| NCT 번호 | 모집 | 조건 | 스폰서/협력자 | 시작일 | 단계 |
|---|---|---|---|---|---|
| NCT05841758 | Not yet recruiting | Sarcoidosis Pulmonary |
Hospices Civils de Lyon |
April 1 2024 | Phase 4 |
| NCT04443270 | Unknown status | COVID-19 |
CMN 20 de Noviembre |
July 27 2020 | Phase 1 |
| NCT04462367 | Active not recruiting | COVID19|Coronavirus Infection|Pregnancy Disease|Severe Acute Respiratory Syndrome |
Instituto Materno Infantil Prof. Fernando Figueira |
July 1 2020 | -- |
| NCT04340544 | Terminated | COVID-19 |
University Hospital Tuebingen|Robert Bosch Medical Center|Universitätsklinikum Hamburg-Eppendorf|Bernhard Nocht Institute for Tropical Medicine |
April 22 2020 | Phase 2 |
| NCT04334148 | Completed | COVID-19 |
Adrian Hernandez|Patient-Centered Outcomes Research Institute|Duke University |
April 22 2020 | Phase 3 |
기술 지원
제품은 연구용으로만 사용됩니다. 인체에는 사용하지 마십시오. 환자에게 판매하지 않습니다.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.